

Trobix Bio Secures New Funding from the Israel Innovation Authority

Netanya, Israel, September 13, 2023 - Trobix Bio, a company utilizing CRISPR, phage, and synthetic biology technologies to develop advanced precision microbiome oncology therapeutics, announces that the Israel Innovation Authority (IIA), the lead R&D supporting arm of the Israeli government, recently approved a non-dilutive grant to Trobix Bio of approximately USD 800,000. The “R&D Fund Program” grant will be used to further support preclinical development of the company’s lead products, TBX201 and TBX301, in preparation towards initiating U.S. investigational new drug studies next year.

“Our significant product development progress over the past year has paved the way to further financial support from the IIA,” said Dr. Adi Elkeles, Founder & CEO of Trobix Bio. “The cumulative funds from non-dilutive sources is now close to USD 3 million or close to 30% of the USD 11 million in total funds raised to date. This IIA funding is playing an especially important role now, during difficult market conditions, enabling us to progress faster and better leverage our investors’ funds as we develop therapeutics to improve outcomes for cancer patients.”

Lead products TBX201 and TBX301 are currently initiating preclinical development to treat severe gastrointestinal side effects of Irinotecan and ICI drugs, respectively. Each therapeutic candidate has already achieved in vitro proof of concept, showing successful reprogramming of targeted bacteria to inhibit irinotecan or ICI related toxicity, respectively.

Trobix previously achieved preclinical efficacy proof of concept with TBX101, an anti-microbial program generated using the same TBX™ technology platform. Although TBX101 development has been put on hold due to the lack of commercial interest in novel anti-microbial agents, its successful preclinical development program serves as a precedent informing and de-risking the new preclinical proof of concept studies being launched now.

Trobix Bio (Netanya, Israel;) is a preclinical stage company working to develop therapeutics that will lead to better outcomes for cancer patients. The proprietary TBX™ platform technology produces orally available phage therapeutic candidates that target and reprogram specific activities in microbiome bacteria using CRISPR. Lead products TBX201 and TBX301 are initiating preclinical development to treat life-threatening gastrointestinal side effects of Irinotecan and ICI drugs, respectively.

For further information please contact:

Trobix Bio

Dr. Adi Elkeles
Chief Executive Officer
Tel: +972-54-6402333
adie@trobixbio.com

Investors & media

Chris Maggos
Cohesion Bureau
+41 79 367 6254
chris.maggos@cohesionbureau.com

